References in periodicals archive ?
Nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, has been approved as a single agent for the first-line treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma, the manufacturer has announced.
According to the Database Safety Monitoring Board (DSMB), the company's IMP321 (Two ACTive Immunotherapeutics in melanoma) is safe and well tolerated at the first dose level when used in combination with a PD-1 blocking antibody and dose escalation can continue as planned.
The efficiency of this HAMA blocking antibody in CARDIAC T Quantitative has been repeatedly tested with heparinized blood samples where plasma was exchanged by two commercial HAMA sera (cat.